Ligand invests up to $47M in AvenCell for royalty on CAR-T pipeline

LIGAND PHARMACEUTICALS INC

Ligand commits $41M for mid single-digit to low double-digit royalty on worldwide net sales of AvenCell pipeline assets, including AVC-201 and AVC-203.
Funding in four tranches; first at closing, rest on clinical milestones and financing conditions.
Ligand also commits up to $6M in AvenCell Series C financing.
AvenCell's lead candidate AVC-201 is in Ph1b for relapsed/refractory AML; AVC-203 in Ph1a for B-cell malignancies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.